Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HR020602
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Administration
- Injection
01
Overview
HR020602 is an investigational drug developed for use in the induction and maintenance of general anesthesia, typically in combination with sedative anesthetics such as propofol. Its precise mechanism of action has not been disclosed or remains unknown. The drug is administered by injection and has been studied primarily in China, including a completed Phase 2 clinical trial evaluating its pharmacokinetics, safety, and efficacy in children undergoing general anesthesia. As of now, it has not received regulatory approval for any indication.
- Other names
- HR-020602HR020602HR 020602
Beyond the preview
Go deeper on HR020602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HR020602.